We’re pleased to announce our investment in Neurode’s $3.5m US seed round alongside Khosla Ventures and Psymed Ventures.ADHD is outpacing standard of care.Attention-deficit-hyperactive disorder (ADHD) is no longer just a quirk in childhood…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2024/10/15zYQymd2N-wcjojmIfdMOw.jpeg6831024Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2024-10-06 06:11:222024-10-07 23:35:12Why we invested in Neurode.
Why we invested in Neurode.We’re pleased to announce our investment in Neurode’s $3.5m US seed round alongside Khosla Ventures and Psymed Ventures.ADHD is outpacing standard of care.Attention-deficit-hyperactive disorder (ADHD) is no longer…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2024/10/1-s35x1qPMloQTfOLx3wT2Q.png2711024Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2024-10-06 06:11:222024-10-07 23:00:22Why we invested in Neurode
We’re pleased to announce our investment in Neurode’s $3.5m US seed round alongside Khosla Ventures and Psymed Ventures.ADHD is outpacing standard of care.Attention-deficit-hyperactive disorder (ADHD) is no longer just a quirk in childhood…
Kinoxis team.We recently announced Kinoxis Therapeutics Pty Ltd $14.5M Series B and our participation in this round. The funds raised will advance their lead candidate (KNX100) into Phase 2 clinical trials targeting agitation and aggression…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2024/09/11lSOK0WxCkC78BI-uCfsaw.jpeg415739Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2024-09-01 13:20:232024-12-10 14:05:10Why we doubled down on Kinoxis.
Meet the newest addition to the Stoic investment teamWith a diverse background spanning start-ups and venture building across Europe, Safaa is eager to leverage her expertise to drive advancements and innovation in healthcare. Her journey, fuelled…
2023 has been another big year at Stoic. We first provide commentary on the venture market this year. We then dig into what we’ve been up to in the past 12 months.Observations of the venture marketThere were a few narratives that dominated…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2023/12/1TwkY1jNQST4dx99e5PiP1Q.png788940Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2023-12-22 00:16:212024-01-10 15:05:08Stoic’s Year in review 2023
2023 has been another big year at Stoic. We first provide commentary on the venture market this year. We then dig into what we’ve been up to in the past 12 months.Observations of the venture marketThere were a few narratives that dominated…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2023/12/1TwkY1jNQST4dx99e5PiP1Q.png788940Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2023-12-22 00:16:212023-12-24 16:30:14Year in review 2023
2023 has been another big year at Stoic. We first provide a commentary on the state of the markets. We then dig into what we’ve been up to in the past 12 months.Observations of the venture marketThere were a few narratives that dominated…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2023/12/1TwkY1jNQST4dx99e5PiP1Q.png788940Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2023-12-22 00:16:212023-12-24 11:35:08Year in review 2023 : Observations of the venture market
A primer on building Neurotech — part 2In part 1 we examined product development and defensibility.In part 2, we look at product delivery and best practice strategies for regulation and reimbursement.Successful product delivery = Longitudinal…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2023/12/1iDRfFxyLc9KjElgMCaNa6g.png7681024Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2023-12-12 10:55:482023-12-12 23:05:09A primer on building Neurotech — part 2
A primer on building Neurotech — part 1The thesis for Neurotech is that by interfacing directly with the nervous system, we can more accurately map the pathophysiology of various neurological & psychiatric disorders. Not just at discrete…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2023/11/1h68uSQBC9pbu4Kzz_EKyyg.png5121024Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2023-11-21 00:37:202023-11-21 21:05:11A primer on building Neurotech — part 1
